Obesity and weight-loss trial programs Type 2 diabetes and glycemic-control research MASLD and liver-fat research Weight-related knee osteoarthritis and pain outcomes Comparisons with semaglutide and tirzepatide Evidence What the research shows The strongest single result available as of May 2026 is the TRIUMPH-4 Phase 3 topline, announced by Lilly on December 11, 2025
Additionally, thermosensitive nanogels and stimuli-responsive nanocarriers that respond to pH or glucose levels have been proposed for precision-controlled GLP-1 delivery, enabling intelligent drug release based on glycemic fluctuations
Neither approach proves universally superior, but individual preference often develops with experience
When these physiological processes become more balanced, many patients notice fewer cravings, improved fullness after meals, and steadier energy throughout the day
The clearest early signs are lower fasting blood sugar readings and more stable energy throughout the day
There is no universally "best" day to inject
